Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma

Teppei Jinno, Shintarou Kawano, Yasuyuki Maruse, Ryota Matsubara, Yuichi Goto, Taiki Sakamoto, Yuma Hashiguchi, Naoki Kaneko, Hideaki Tanaka, ryoji kitamura, Takeshi Toyoshima, Akiko Jinno, Masafumi Moriyama, Kazunari Oobu, Tamotsu Kiyoshima, Seiji Nakamura

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Recent studies have revealed that cancer cells are exacerbated by chronic inflammation. The present study examined the immunohistochemical expression for interleukin-6 (IL-6), a pleiotropic inflammatory cytokine, in oral squamous cell carcinoma (OSCC) to elucidate the association of IL-6 expression with tumor progression, chemoresistance and prognosis. Seventy-eight patients with primary OSCC were analyzed by immunohistochemical staining for IL-6. These labeling indexes (LIs) were calculated and evaluated in association with the clinicopathologic characteristics and prognosis in the OSCC patients. The patients were divided into three groups as follows: n egative g roup = L I < 5%; low I L-6 g roup = 5% ≤ LI <30%; high IL-6 group = LI ≥30%. The patient numbers of the negative, low and high expression groups were 24, 22 and 32, respectively. In the high IL-6 expression group, IL-6 receptor (IL-6R), phospho-signal tranducer and activator of transcription 3 (p-STAT3) were also detected in almost all the cancer cells. The prevalence of the cervical lymph node or the distant metastasis in the high expression group was significantly higher than those in the negative and low expression groups. Furthermore, the high expression group had a significantly poorer tumor response to the preoperative chemoradiotherapy and a more unfavourable prognosis than the negative and the low expression groups. Interestingly, IL-6, IL-6R and p-STAT3 were expressed in the residual cancer cells of all the patients in the high expression group with poor response to chemoradiotherapy. These results suggested that IL-6 signaling possibly is involved in the progression and treatment-resistance of OSCC and IL-6 expression in cancer cells could be a useful predictive factor of poor response to chemoradiotherapy and unfavorable prognosis.

Original languageEnglish
Pages (from-to)2161-2168
Number of pages8
JournalOncology reports
Volume33
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Chemoradiotherapy
Squamous Cell Carcinoma
Interleukin-6
Interleukin-6 Receptors
Neoplasms
Residual Neoplasm
Lymph Nodes
Staining and Labeling
Cytokines
Neoplasm Metastasis
Inflammation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma. / Jinno, Teppei; Kawano, Shintarou; Maruse, Yasuyuki; Matsubara, Ryota; Goto, Yuichi; Sakamoto, Taiki; Hashiguchi, Yuma; Kaneko, Naoki; Tanaka, Hideaki; kitamura, ryoji; Toyoshima, Takeshi; Jinno, Akiko; Moriyama, Masafumi; Oobu, Kazunari; Kiyoshima, Tamotsu; Nakamura, Seiji.

In: Oncology reports, Vol. 33, No. 5, 01.05.2015, p. 2161-2168.

Research output: Contribution to journalArticle

@article{ab4d1d1a62a4406f924b28b6dac2cbe3,
title = "Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma",
abstract = "Recent studies have revealed that cancer cells are exacerbated by chronic inflammation. The present study examined the immunohistochemical expression for interleukin-6 (IL-6), a pleiotropic inflammatory cytokine, in oral squamous cell carcinoma (OSCC) to elucidate the association of IL-6 expression with tumor progression, chemoresistance and prognosis. Seventy-eight patients with primary OSCC were analyzed by immunohistochemical staining for IL-6. These labeling indexes (LIs) were calculated and evaluated in association with the clinicopathologic characteristics and prognosis in the OSCC patients. The patients were divided into three groups as follows: n egative g roup = L I < 5{\%}; low I L-6 g roup = 5{\%} ≤ LI <30{\%}; high IL-6 group = LI ≥30{\%}. The patient numbers of the negative, low and high expression groups were 24, 22 and 32, respectively. In the high IL-6 expression group, IL-6 receptor (IL-6R), phospho-signal tranducer and activator of transcription 3 (p-STAT3) were also detected in almost all the cancer cells. The prevalence of the cervical lymph node or the distant metastasis in the high expression group was significantly higher than those in the negative and low expression groups. Furthermore, the high expression group had a significantly poorer tumor response to the preoperative chemoradiotherapy and a more unfavourable prognosis than the negative and the low expression groups. Interestingly, IL-6, IL-6R and p-STAT3 were expressed in the residual cancer cells of all the patients in the high expression group with poor response to chemoradiotherapy. These results suggested that IL-6 signaling possibly is involved in the progression and treatment-resistance of OSCC and IL-6 expression in cancer cells could be a useful predictive factor of poor response to chemoradiotherapy and unfavorable prognosis.",
author = "Teppei Jinno and Shintarou Kawano and Yasuyuki Maruse and Ryota Matsubara and Yuichi Goto and Taiki Sakamoto and Yuma Hashiguchi and Naoki Kaneko and Hideaki Tanaka and ryoji kitamura and Takeshi Toyoshima and Akiko Jinno and Masafumi Moriyama and Kazunari Oobu and Tamotsu Kiyoshima and Seiji Nakamura",
year = "2015",
month = "5",
day = "1",
doi = "10.3892/or.2015.3838",
language = "English",
volume = "33",
pages = "2161--2168",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma

AU - Jinno, Teppei

AU - Kawano, Shintarou

AU - Maruse, Yasuyuki

AU - Matsubara, Ryota

AU - Goto, Yuichi

AU - Sakamoto, Taiki

AU - Hashiguchi, Yuma

AU - Kaneko, Naoki

AU - Tanaka, Hideaki

AU - kitamura, ryoji

AU - Toyoshima, Takeshi

AU - Jinno, Akiko

AU - Moriyama, Masafumi

AU - Oobu, Kazunari

AU - Kiyoshima, Tamotsu

AU - Nakamura, Seiji

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Recent studies have revealed that cancer cells are exacerbated by chronic inflammation. The present study examined the immunohistochemical expression for interleukin-6 (IL-6), a pleiotropic inflammatory cytokine, in oral squamous cell carcinoma (OSCC) to elucidate the association of IL-6 expression with tumor progression, chemoresistance and prognosis. Seventy-eight patients with primary OSCC were analyzed by immunohistochemical staining for IL-6. These labeling indexes (LIs) were calculated and evaluated in association with the clinicopathologic characteristics and prognosis in the OSCC patients. The patients were divided into three groups as follows: n egative g roup = L I < 5%; low I L-6 g roup = 5% ≤ LI <30%; high IL-6 group = LI ≥30%. The patient numbers of the negative, low and high expression groups were 24, 22 and 32, respectively. In the high IL-6 expression group, IL-6 receptor (IL-6R), phospho-signal tranducer and activator of transcription 3 (p-STAT3) were also detected in almost all the cancer cells. The prevalence of the cervical lymph node or the distant metastasis in the high expression group was significantly higher than those in the negative and low expression groups. Furthermore, the high expression group had a significantly poorer tumor response to the preoperative chemoradiotherapy and a more unfavourable prognosis than the negative and the low expression groups. Interestingly, IL-6, IL-6R and p-STAT3 were expressed in the residual cancer cells of all the patients in the high expression group with poor response to chemoradiotherapy. These results suggested that IL-6 signaling possibly is involved in the progression and treatment-resistance of OSCC and IL-6 expression in cancer cells could be a useful predictive factor of poor response to chemoradiotherapy and unfavorable prognosis.

AB - Recent studies have revealed that cancer cells are exacerbated by chronic inflammation. The present study examined the immunohistochemical expression for interleukin-6 (IL-6), a pleiotropic inflammatory cytokine, in oral squamous cell carcinoma (OSCC) to elucidate the association of IL-6 expression with tumor progression, chemoresistance and prognosis. Seventy-eight patients with primary OSCC were analyzed by immunohistochemical staining for IL-6. These labeling indexes (LIs) were calculated and evaluated in association with the clinicopathologic characteristics and prognosis in the OSCC patients. The patients were divided into three groups as follows: n egative g roup = L I < 5%; low I L-6 g roup = 5% ≤ LI <30%; high IL-6 group = LI ≥30%. The patient numbers of the negative, low and high expression groups were 24, 22 and 32, respectively. In the high IL-6 expression group, IL-6 receptor (IL-6R), phospho-signal tranducer and activator of transcription 3 (p-STAT3) were also detected in almost all the cancer cells. The prevalence of the cervical lymph node or the distant metastasis in the high expression group was significantly higher than those in the negative and low expression groups. Furthermore, the high expression group had a significantly poorer tumor response to the preoperative chemoradiotherapy and a more unfavourable prognosis than the negative and the low expression groups. Interestingly, IL-6, IL-6R and p-STAT3 were expressed in the residual cancer cells of all the patients in the high expression group with poor response to chemoradiotherapy. These results suggested that IL-6 signaling possibly is involved in the progression and treatment-resistance of OSCC and IL-6 expression in cancer cells could be a useful predictive factor of poor response to chemoradiotherapy and unfavorable prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84927164392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927164392&partnerID=8YFLogxK

U2 - 10.3892/or.2015.3838

DO - 10.3892/or.2015.3838

M3 - Article

C2 - 25761055

AN - SCOPUS:84927164392

VL - 33

SP - 2161

EP - 2168

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -